TY - JOUR A1 - Wunsch, Marie A1 - Hohmann, Christopher A1 - Milles, Bianca A1 - Rostermund, Christina A1 - Lehmann, Paul V. A1 - Schroeter, Michael A1 - Bayas, Antonios A1 - Ulzheimer, Jochen A1 - Mäurer, Mathias A1 - Ergün, Süleyman A1 - Kuerten, Stefanie T1 - The Correlation between the Virus- and Brain Antigen-Specific B Cell Response in the Blood of Patients with Multiple Sclerosis JF - Viruses N2 - There is a largely divergent body of literature regarding the relationship between Epstein-Barr virus (EBV) infection and brain inflammation in multiple sclerosis (MS). Here, we tested MS patients during relapse (n = 11) and in remission (n = 19) in addition to n = 22 healthy controls to study the correlation between the EBV- and brain-specific B cell response in the blood by enzyme-linked immunospot (ELISPOT) and enzyme-linked immunosorbent assay (ELISA). Cytomegalovirus (CMV) was used as a control antigen tested in n = 16 MS patients during relapse and in n = 35 patients in remission. Over the course of the study, n = 16 patients were untreated, while n = 33 patients received immunomodulatory therapy. The data show that there was a moderate correlation between the frequencies of EBV- and brain-reactive B cells in MS patients in remission. In addition we could detect a correlation between the B cell response to EBV and disease activity. There was no evidence of an EBV reactivation. Interestingly, there was also a correlation between the frequencies of CMV- and brain-specific B cells in MS patients experiencing an acute relapse and an elevated B cell response to CMV was associated with higher disease activity. The trend remained when excluding seronegative subjects but was non-significant. These data underline that viral infections might impact the immunopathology of MS, but the exact link between the two entities remains subject of controversy. KW - B cells KW - CMV KW - EBV KW - ELISPOT KW - MS Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-146946 VL - 8 IS - 4 ER - TY - THES A1 - Buchner, Stefan T1 - Quantitative 31P-MR-Spektroskopie am menschlichen Herzen und Etablierung von SLOOP am Skelettmuskel T1 - Quantitative 31P-MR-Spectroscopy of the human myocardium and establishment of SLOOP on skeletal muscle N2 - Die vorliegende Arbeit setzt sich mit dem Einsatz der 31P-Magnetresonanzspektroskopie (MRS) zur Untersuchung des menschlichen Herz- und Skelettmuskelstoffwechsels auseinander: [1] Mit der Anwendung und Implementierung der akquisitionsgewichteten CSI (AW-CSI) am menschlichen Herzen konnten wir den Einsatz dieser neuen Methode zur 31P-MR-Bildgebung am klinischen MR-Gerät etablieren. [2] Mit dem erstmaligen Einsatz von SLOOP am Skelettmuskel zur nicht-invasiven Quantifizierung des Energiestoffwechsels mit 31P-MRS erarbeiteten wir neue Untersuchungsprotokolle und konnten sie erfolgreich bei Probanden anwenden. [3] Mit der 31P-MRs konnten wir durch Bestimmung des PCr/ATP Verhältnisses Einflüsse und Veränderungen im Energiestoffwechsel sowohl im infarzierten als auch im nicht-infarzierten Myokard bei Patienten mit vitalem und avitalem anterioren Infarkt nachweisen (FAST). [4] Mit der klinischen Anwendung von SLOOP wurden subklinische Stoffwechselveränderungen bei Patienten mit multipler Sklerose (MS) und bei mit Mitoxantron (MX) therapierten MS-Patienten eruiert. [5] Mit dem erstmalig kombinierten Einsatz von SLOOP bei neuromuskulären Erkrankungen wie myotoner Dystrophie (DM1) und proximaler myotoner Myopathie (PROMM/DM2) wurden Zusammenhänge zwischen Krankheitsdauer, Krankheitsverlauf, Muskelschwäche und dem kardialen und skelettmuskulären Energiestoffwechsel untersucht, um zusätzliche Informationen zum Verständnis der Pathogenese und Entwicklung von DM1 und PROMM/DM2 zu gewinnen. N2 - The purpose of the study was KW - SLOOP KW - PROMM KW - DM KW - MS KW - Mitoxantron KW - AW-CSI KW - 31P KW - MR KW - Spektroskopie KW - PCr KW - ATP KW - Myokardinfarkt KW - SLOOP KW - PROMM KW - DM KW - MS KW - Mitoxantrone KW - AW-CSI KW - 31P KW - MR KW - spectroscopy KW - PCr KW - ATP KW - myocardial infarction Y1 - 2003 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-9071 ER - TY - JOUR A1 - Rajendran, Ranjithkumar A1 - Rajendran, Vinothkumar A1 - Giraldo-Velasquez, Mario A1 - Megalofonou, Fevronia-Foivi A1 - Gurski, Fynn A1 - Stadelmann, Christine A1 - Karnati, Srikanth A1 - Berghoff, Martin T1 - Oligodendrocyte-specific deletion of FGFR1 reduces cerebellar inflammation and neurodegeneration in MOG\(_{35-55}\)-induced EAE JF - International Journal of Molecular Sciences N2 - Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system (CNS). MS commonly affects the cerebellum causing acute and chronic symptoms. Cerebellar signs significantly contribute to clinical disability, and symptoms such as tremor, ataxia, and dysarthria are difficult to treat. Fibroblast growth factors (FGFs) and their receptors (FGFRs) are involved in demyelinating pathologies such as MS. In autopsy tissue from patients with MS, increased expression of FGF1, FGF2, FGF9, and FGFR1 was found in lesion areas. Recent research using mouse models has focused on regions such as the spinal cord, and data on the expression of FGF/FGFR in the cerebellum are not available. In recent EAE studies, we detected that oligodendrocyte-specific deletion of FGFRs results in a milder disease course, less cellular infiltrates, and reduced neurodegeneration in the spinal cord. The objective of this study was to characterize the role of FGFR1 in oligodendrocytes in the cerebellum. Conditional deletion of FGFR1 in oligodendrocytes (Fgfr1\(^{ind−/−}\) was achieved by tamoxifen application, EAE was induced using the MOG\(_{35-55}\) peptide. The cerebellum was analyzed by histology, immunohistochemistry, and western blot. At day 62 p.i., Fgfr1\(^{ind−/−}\) mice showed less myelin and axonal degeneration compared to FGFR1-competent mice. Infiltration of CD3(+) T cells, Mac3(+) cells, B220(+) B cells and IgG(+) plasma cells in cerebellar white matter lesions (WML) was less in Fgfr1\(^{ind−/−}\)mice. There were no effects on the number of OPC or mature oligodendrocytes in white matter lesion (WML). Expression of FGF2 and FGF9 associated with less myelin and axonal degeneration, and of the pro-inflammatory cytokines IL-1β, IL-6, and CD200 was downregulated in Fgfr1\(^{ind−/−}\) mice. The FGF/FGFR signaling protein pAkt, BDNF, and TrkB were increased in Fgfr1\(^{ind−/−}\) mice. These data suggest that cell-specific deletion of FGFR1 in oligodendrocytes has anti-inflammatory and neuroprotective effects in the cerebellum in the EAE disease model of MS. KW - FGFR1 KW - oligodendrocytes KW - demyelination KW - inflammation KW - cerebellum KW - EAE KW - MS Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-284296 SN - 1422-0067 VL - 22 IS - 17 ER - TY - JOUR A1 - Brecht, Isabel A1 - Weissbrich, Benedikt A1 - Braun, Julia A1 - Toyka, Klaus Viktor A1 - Weishaupt, Andreas A1 - Buttmann, Mathias T1 - Intrathecal, Polyspecific Antiviral Immune Response in Oligoclonal Band Negative Multiple Sclerosis JF - PLoS One N2 - Background: Oligoclonal bands (OCB) are detected in the cerebrospinal fluid (CSF) in more than 95% of patients with multiple sclerosis (MS) in the Western hemisphere. Here we evaluated the intrathecal, polyspecific antiviral immune response as a potential diagnostic CSF marker for OCB-negative MS patients. Methodology/Principal Findings: We tested 46 OCB-negative German patients with paraclinically well defined, definite MS. Sixteen OCB-negative patients with a clear diagnosis of other autoimmune CNS disorders and 37 neurological patients without evidence for autoimmune CNS inflammation served as control groups. Antibodies against measles, rubella, varicella zoster and herpes simplex virus in paired serum and CSF samples were determined by ELISA, and virus-specific immunoglobulin G antibody indices were calculated. An intrathecal antibody synthesis against at least one neurotropic virus was detected in 8 of 26 (31%) patients with relapsing-remitting MS, 8 of 12 (67%) with secondary progressive MS and 5 of 8 (63%) with primary progressive MS, in 3 of 16 (19%) CNS autoimmune and 3 of 37 (8%) non-autoimmune control patients. Antibody synthesis against two or more viruses was found in 11 of 46 (24%) MS patients but in neither of the two control groups. On average, MS patients with a positive antiviral immune response were older and had a longer disease duration than those without. Conclusion: Determination of the intrathecal, polyspecific antiviral immune response may allow to establish a CSF-supported diagnosis of MS in OCB-negative patients when two or more of the four virus antibody indices are elevated. KW - MS KW - cerebrospinal fluid KW - differential diagnosis KW - nervous-system KW - criteria KW - serum Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-134426 VL - 7 IS - 7 ER - TY - JOUR A1 - Huss, André M. A1 - Halbgebauer, Steffen A1 - Öckl, Patrick A1 - Trebst, Corinna A1 - Spreer, Annette A1 - Borisow, Nadja A1 - Harrer, Andrea A1 - Brecht, Isabel A1 - Balint, Bettina A1 - Stich, Oliver A1 - Schlegel, Sabine A1 - Retzlaff, Nele A1 - Winkelmann, Alexander A1 - Roesler, Romy A1 - Lauda, Florian A1 - Yildiz, Özlem A1 - Voß, Elke A1 - Muche, Rainer A1 - Rauer, Sebastian A1 - Bergh, Florian Then A1 - Otto, Markus A1 - Paul, Friedemann A1 - Wildemann, Brigitte A1 - Kraus, Jörg A1 - Ruprecht, Klemens A1 - Stangel, Martin A1 - Buttmann, Mathias A1 - Zettl, Uwe K. A1 - Tumani, Hayrettin T1 - Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome JF - Journal of Neurology N2 - The majority of patients presenting with a first clinical symptom suggestive of multiple sclerosis (MS) do not fulfill the MRI criteria for dissemination in space and time according to the 2010 revision of the McDonald diagnostic criteria for MS and are thus classified as clinically isolated syndrome (CIS). To re-evaluate the utility of cerebrospinal fluid (CSF) analysis in the context of the revised McDonald criteria from 2010, we conducted a retrospective multicenter study aimed at determining the prevalence and predictive value of oligoclonal IgG bands (OCBs) in patients with CIS. Patients were recruited from ten specialized MS centers in Germany and Austria. We collected data from 406 patients; at disease onset, 44/406 (11 %) fulfilled the McDonald 2010 criteria for MS. Intrathecal IgG OCBs were detected in 310/362 (86 %) of CIS patients. Those patients were twice as likely to convert to MS according to McDonald 2010 criteria as OCB-negative individuals (hazard ratio = 2.1, p = 0.0014) and in a shorter time period of 25 months (95 % CI 21-34) compared to 47 months in OCB-negative individuals (95 % CI 36-85). In patients without brain lesions at first attack and presence of intrathecal OCBs (30/44), conversion rate to MS was 60 % (18/30), whereas it was only 21 % (3/14) in those without OCBs. Our data confirm that in patients with CIS the risk of conversion to MS substantially increases if OCBs are present at onset. CSF analysis definitely helps to evaluate the prognosis in patients who do not have MS according to the revised McDonald criteria. KW - multiple sklerosis KW - MRI criteria KW - conversion KW - MS KW - CSF KW - biomarker KW - OCB Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-186619 VL - 263 IS - 12 ER - TY - THES A1 - Oehler, Steffen Claus T1 - Deeskalation der Immuntherapie bei Patienten mit Multipler Sklerose T1 - Deescalation of Immuntherapy in patients with Multiple Sclerosis N2 - Die vorliegende Arbeit ist die erste, die sich mit der Frage beschäftigt, mit welcher zur Deeskalation eingesetzten Therapie nach Beendigung einer Eskalationstherapie mit Mitoxantron am besten Krankheitsstabilität erreicht werden kann bzw. ob Patienten-/Krankheitscharakteristika existieren, die eine bestimmte Nachfolge-Therapie favorisieren. Trotz neuer Behandlungsmöglichkeiten der hochaktiven MS mit Fingolimod, Natalizumab und Alemtuzumab hat Mitoxantron im klinischen Alltag nach wie vor einen hohen Stellenwert, so dass die Fragestellung dieser Studie weiter relevant ist. Es zeigten sich keine Patientencharakteristika, die auf eine erfolgsversprechende Therapie in der Deeskalationsphase nach Mitoxantron schließen ließen. Bei Patienten, bei denen während der Eskalation mit Mitoxantron die Dosis reduziert werden konnte, wurden während der Deeskalationstherapie ein stabilerer Verlauf und weniger Therapiewechsel beobachtet. Bei Patienten, die wegen einer rein chronischen Krankheitsprogredienz eskaliert wurden, trat eine Verschlechterung nach Deeskalation häufiger auf als bei denjenigen, welche wegen Schubaktivität eskaliert wurden. Die Aussagekraft der Daten wird durch die nur niedrige Anzahl der in diese Studie eingeschlossenen Patienten limitiert. Rekrutierungsprobleme stellten die Hauptursache für die geringe Anzahl der Studienteilnehmer dar. N2 - Deescalation of Immuntherapy in patients with Multiple Sclerosis KW - Multiple Sklerose KW - Mitoxantron KW - Deeskalation KW - MS KW - Deeskalationstherapie Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133666 ER - TY - JOUR A1 - Schampel, Andrea A1 - Kuerten, Stefanie T1 - Danger: high voltage - the role of voltage-gated calcium channels in central nervous system pathology JF - Cells N2 - Voltage-gated calcium channels (VGCCs) are widely distributed within the central nervous system (CNS) and presumed to play an important role in the pathophysiology of a broad spectrum of CNS disorders including Alzheimer’s and Parkinson’s disease as well as multiple sclerosis. Several calcium channel blockers have been in clinical practice for many years so that their toxicity and side effects are well studied. However, these drugs are primarily used for the treatment of cardiovascular diseases and most if not all effects on brain functions are secondary to peripheral effects on blood pressure and circulation. While the use of calcium channel antagonists for the treatment of CNS diseases therefore still heavily depends on the development of novel strategies to specifically target different channels and channel subunits, this review is meant to provide an impulse to further emphasize the importance of future research towards this goal. KW - cells KW - calcium KW - calcium channel antagonists KW - CNS KW - EAE KW - neurodegeneration KW - MS KW - regeneration KW - remyelination Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-172653 VL - 6 IS - 4 ER - TY - THES A1 - Deubel, Alexandra T1 - Charakterisierung des Verunreinigungsprofils von Erythromycin mittels chromatographischer Methoden und massenspektrometrischer Detektion T1 - Characterization of the Impurity Profile of Erythromycin by means of chromatographic methods and mass spectrometric Detection N2 - Im Rahmen der vorliegenden Arbeit wurden analytische Methoden zur Bestimmung des Verunreinigungsprofils von Erythromycin entwickelt, die der bestehenden Ph.Eur.-Methode überlegen sind. Die neue HPLC-Methode ist in der Lage, alle verwandten Verbindungen mit angemessener Präzision nachzuweisen und zu quantifizieren. Mit Hilfe der Massenspektrometrie konnten alle Hauptkomponenten und verwandten Verbindungen der Base, ihrer Ester und Salze eindeutig identifiziert und quantifiziert werden. Zudem konnten zwei neue verwandte Verbindungen von Erythromycin gefunden und als N,N-Didemethylerythromycin A und Anhydroerythromycin F identifiziert werden. N2 - Within this work analytical methods for determination of the impurity profile of erythromycin were developed. These methods show clear improvements compared to the current methods described in the Ph.Eur. The new HPLC method is able to separate and quantify all related substances with an acceptable precision. The mass spectrometry shows the suitability for the direct qualitative and quantitative analysis of the base, ester and salts of erythromycin. Moreover using ion trap two new, unexpected EA related substances could be detected and identified as N,N-didemethylerythromycin A and anhydroerythromycin F. KW - Erythromycin KW - Verunreinigung KW - HPLC KW - Massenspektrometrie KW - Erythromycin KW - HPLC KW - MS KW - Verunreinigungsprofil KW - neue Verunreinigungen KW - erythromycin KW - HPLC KW - mass spectrometry KW - new impurities Y1 - 2006 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-20160 ER - TY - JOUR A1 - Hohnmann, Christopher A1 - Milles, Bianca A1 - Schinke, Michael A1 - Schroeter, Michael A1 - Ulzheimer, Jochen A1 - Kraft, Peter A1 - Kleinschnitz, Christoph A1 - Lehmann, Paul V. A1 - Kuerten, Stefanie T1 - Categorization of multiple sclerosis relapse subtypes by B cell profiling in the blood JF - Acta Neuropathologica Communications N2 - Introduction B cells are attracting increasing attention in the pathogenesis of multiple sclerosis (MS). B cell-targeted therapies with monoclonal antibodies or plasmapheresis have been shown to be successful in a subset of patients. Here, patients with either relapsing-remitting (n = 24) or secondary progressive (n = 6) MS presenting with an acute clinical relapse were screened for their B cell reactivity to brain antigens and were re-tested three to nine months later. Enzyme-linked immunospot technique (ELISPOT) was used to identify brain-reactive B cells in peripheral blood mononuclear cells (PBMC) directly ex vivo and after 96 h of polyclonal stimulation. Clinical severity of symptoms was determined using the Expanded Disability Status Scale (EDSS). Results Nine patients displayed B cells in the blood producing brain-specific antibodies directly ex vivo. Six patients were classified as B cell positive donors only after polyclonal B cell stimulation. In 15 patients a B cell response to brain antigens was absent. Based on the autoreactive B cell response we categorized MS relapses into three different patterns. Patients who displayed brain-reactive B cell responses both directly ex vivo and after polyclonal stimulation (pattern I) were significantly younger than patients in whom only memory B cell responses were detectable or entirely absent (patterns II and III; p = 0.003). In one patient a conversion to a positive B cell response as measured directly ex vivo and subsequently also after polyclonal stimulation was associated with the development of a clinical relapse. The evaluation of the predictive value of a brain antigen-specific B cell response showed that seven of eight patients (87.5%) with a pattern I response encountered a clinical relapse during the observation period of 10 months, compared to two of five patients (40%) with a pattern II and three of 14 patients (21.4%) with a pattern III response (p = 0.0005; hazard ratio 6.08 (95% confidence interval 1.87-19.77). Conclusions Our data indicate actively ongoing B cell-mediated immunity against brain antigens in a subset of MS patients that may be causative of clinical relapses and provide new diagnostic and therapeutic options for a subset of patients. KW - predictive value KW - MS KW - ELISPOT KW - B cells KW - relapse Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-126124 VL - 2 IS - 138 ER - TY - JOUR A1 - Hohmann, Christopher A1 - Milles, Bianca A1 - Schinke, Michael A1 - Schroeter, Michael A1 - Ulzheimer, Jochen A1 - Kraft, Peter A1 - Kleinschnitz, Christoph A1 - Lehmann, Paul V. A1 - Kuerten, Stefanie T1 - Categorization of multiple sclerosis relapse subtypes by B cell profiling in the blood JF - Acta Neuropathologica Communications N2 - INTRODUCTION: B cells are attracting increasing attention in the pathogenesis of multiple sclerosis (MS). B cell-targeted therapies with monoclonal antibodies or plasmapheresis have been shown to be successful in a subset of patients. Here, patients with either relapsing-remitting (n = 24) or secondary progressive (n = 6) MS presenting with an acute clinical relapse were screened for their B cell reactivity to brain antigens and were re-tested three to nine months later. Enzyme-linked immunospot technique (ELISPOT) was used to identify brain-reactive B cells in peripheral blood mononuclear cells (PBMC) directly ex vivo and after 96 h of polyclonal stimulation. Clinical severity of symptoms was determined using the Expanded Disability Status Scale (EDSS). RESULTS: Nine patients displayed B cells in the blood producing brain-specific antibodies directly ex vivo. Six patients were classified as B cell positive donors only after polyclonal B cell stimulation. In 15 patients a B cell response to brain antigens was absent. Based on the autoreactive B cell response we categorized MS relapses into three different patterns. Patients who displayed brain-reactive B cell responses both directly ex vivo and after polyclonal stimulation (pattern I) were significantly younger than patients in whom only memory B cell responses were detectable or entirely absent (patterns II and III; p = 0.003). In one patient a conversion to a positive B cell response as measured directly ex vivo and subsequently also after polyclonal stimulation was associated with the development of a clinical relapse. The evaluation of the predictive value of a brain antigen-specific B cell response showed that seven of eight patients (87.5%) with a pattern I response encountered a clinical relapse during the observation period of 10 months, compared to two of five patients (40%) with a pattern II and three of 14 patients (21.4%) with a pattern III response (p = 0.0005; hazard ratio 6.08 (95% confidence interval 1.87-19.77). CONCLUSIONS: Our data indicate actively ongoing B cell-mediated immunity against brain antigens in a subset of MS patients that may be causative of clinical relapses and provide new diagnostic and therapeutic options for a subset of patients. KW - ELISPOT KW - MS KW - predictive value KW - relapse KW - B cells Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-120580 SN - 2051-5960 VL - 2 IS - 138 ER - TY - JOUR A1 - Simon, Micha A1 - Ipek, Rojda A1 - Homola, György A. A1 - Rovituso, Damiano M. A1 - Schampel, Andrea A1 - Kleinschnitz, Christoph A1 - Kuerten, Stefanie T1 - Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis JF - Journal of Neuroinflammation N2 - Background: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) for which several new treatment options were recently introduced. Among them is the monoclonal anti-CD52 antibody alemtuzumab that depletes mainly B cells and T cells in the immune periphery. Considering the ongoing controversy about the involvement of B cells and in particular the formation of B cell aggregates in the brains of progressive MS patients, an in-depth understanding of the effects of anti-CD52 antibody treatment on the B cell compartment in the CNS itself is desirable. Methods: We used myelin basic protein (MBP)-proteolipid protein (PLP)-induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 (B6) mice as B cell-dependent model of MS. Mice were treated intraperitoneally either at the peak of EAE or at 60 days after onset with 200 μg murine anti-CD52 vs. IgG2a isotype control antibody for five consecutive days. Disease was subsequently monitored for 10 days. The antigen-specific B cell/antibody response was measured by ELISPOT and ELISA. Effects on CNS infiltration and B cell aggregation were determined by immunohistochemistry. Neurodegeneration was evaluated by Luxol Fast Blue, SMI-32, and Olig2/APC staining as well as by electron microscopy and phosphorylated heavy neurofilament serum ELISA. Results: Treatment with anti-CD52 antibody attenuated EAE only when administered at the peak of disease. While there was no effect on the production of MP4-specific IgG, the treatment almost completely depleted CNS infiltrates and B cell aggregates even when given as late as 60 days after onset. On the ultrastructural level, we observed significantly less axonal damage in the spinal cord and cerebellum in chronic EAE after anti-CD52 treatment. Conclusion: Anti-CD52 treatment abrogated B cell infiltration and disrupted existing B cell aggregates in the CNS. KW - Alemtuzumab KW - B cells KW - CD52 KW - CNS KW - EAE KW - MS Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-176120 VL - 15 IS - 225 ER -